Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/17749

TDMS Study 93021-05 Pathology Tables

NTP Experiment-Test: 93021-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DICYCLOHEXYLCARBODIIMIDE                                 Date: 09/02/97
Route: SKIN APPLICATION                                                                                           Time: 10:20:20

                                                       150 DAY SUBCHRONIC




       Facility:  Microbiological Associates

       Chemical CAS #:  538-75-0

       Lock Date:  03/26/96

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93021-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DICYCLOHEXYLCARBODIIMIDE                                 Date: 09/02/97  
Route: SKIN APPLICATION                                                                                           Time: 10:20:20  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            .75          1.5          3            6            12              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 

  Animals Initially in Study                          10           10           10           10           10           10           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 2            2                         2            2                        
    Natural Death                                      1            1                         1                         1           
    Accidently Killed                                                                         1                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                 7            7           10            6            8            9           

  Animals Examined Microscopically                    10           10           10           10           10           10           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (10)         (6)          (6)          (7)          (10)         (10)         
      Leukemia Erythrocytic                            1 (10%)                   2 (33%)                   1 (10%)                  
   Pancreas                                           (10)         (3)                       (4)          (2)          (10)         
      Leukemia Erythrocytic                                                                                1 (50%)                  
   Stomach, Forestomach                               (10)         (4)          (2)          (5)          (4)          (10)         
      Squamous Cell Papilloma                                       2 (50%)      2 (100%)     1 (20%)      1 (25%)                  
   Tooth                                              (4)          (5)          (6)          (4)          (5)          (5)          
      Odontoma                                         3 (75%)      5 (100%)     6 (100%)     3 (75%)      5 (100%)     5 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Thyroid Gland                                      (9)          (4)                       (4)          (2)          (10)         
      C-Cell, Adenoma                                               1 (25%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    

                                                             Page   2                                                               
NTP Experiment-Test: 93021-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DICYCLOHEXYLCARBODIIMIDE                                 Date: 09/02/97  
Route: SKIN APPLICATION                                                                                           Time: 10:20:20  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            .75          1.5          3            6            12              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                                      (1)                                    (1)                       
      Leukemia Erythrocytic                                                                                1 (100%)                 
   Spleen                                             (10)         (5)          (5)          (4)          (4)          (10)         
      Leukemia Erythrocytic                                                      2 (40%)                   1 (25%)                  
   Thymus                                             (9)          (3)                       (3)          (2)          (10)         
      Lymphoma Malignant                               1 (11%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (10)         (10)         (10)         (10)         (10)         (10)         
      Squamous Cell Papilloma                                                    1 (10%)                                1 (10%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                                                        1 (10%)                  
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           3 (30%)      3 (30%)      3 (30%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                    1 (10%)                   3 (30%)      5 (50%)     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             

                                                             Page   3                                                               
NTP Experiment-Test: 93021-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DICYCLOHEXYLCARBODIIMIDE                                 Date: 09/02/97  
Route: SKIN APPLICATION                                                                                           Time: 10:20:20  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            .75          1.5          3            6            12              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   

   Multiple Organs                                   *(10)        *(10)        *(10)        *(10)        *(10)        *(10)         
      Leukemia Erythrocytic                            1 (10%)                   2 (20%)                   1 (10%)                  
      Lymphoma Malignant                               1 (10%)                                                                      
____________________________________________________________________________________________________________________________________

                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 

                                                             Page   4                                                               
NTP Experiment-Test: 93021-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DICYCLOHEXYLCARBODIIMIDE                                 Date: 09/02/97  
Route: SKIN APPLICATION                                                                                           Time: 10:20:20  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            .75          1.5          3            6            12              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             5           6           9           6           8          10               
     Total Primary Neoplasms                            5           8          12           7          14          14               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  3           6           8           6           8          10               
     Total Benign Neoplasms                             3           8          10           7          12          14               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               2                       2                       2                           
     Total Malignant Neoplasms                          2                       2                       2                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    

____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              

                                                             Page   5                                                               
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------